Biopharmaceutics & Drug disPosition

Papers
(The median citation count of Biopharmaceutics & Drug disPosition is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
21
In situ evaluation of the impact of metformin or verapamil coadministration with vildagliptin on its regional absorption from the rabbit’s intestine17
16
Decreased plasma acetaminophen glucuronide/acetaminophen concentration ratio warns the onset of acetaminophen‐induced liver injury14
Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS14
Aging and brain free cholesterol concentration on amyloid‐β peptide accumulation in guinea pigs12
Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling11
Issue Information10
9
Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling – A case study of dextromethorphan modified release tablets9
Self‐micellizing solid dispersion of tacrolimus: Physicochemical and pharmacokinetic characterization9
Issue Information8
Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling8
Issue Information8
Attenuation of phenobarbital‐induced cytochrome P450 expression in carbon tetrachloride‐induced hepatitis in mice models7
Issue Information7
Issue Information7
Utility of cystatin C and serum creatinine‐based glomerular filtration rate equations in predicting vancomycin clearance: A population pharmacokinetics analysis in elderly Chinese patients7
Evidence for cytochrome P450 3A4‐mediated metabolic activation of SCO‐2677
Novel Enteric Microsphere of Beclomethasone Dipropionate With Colon Delivery and Enhancement of Anti‐Inflammatory Effects6
Irinotecan‐induced gastrointestinal damage alters the expression of peptide transporter 1 and absorption of cephalexin in rats6
Metabolism and pharmacokinetic study of deuterated osimertinib6
Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output6
Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor6
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐815
Species Differences in Carboxylesterases Among Humans, Cynomolgus Monkeys, and Mice in the Hydrolysis of Atorvastatin Derivatives5
Pharmacokinetic control of orally dosed cyclosporine A with mucosal drug delivery system5
Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells5
Norvancomycin plasma concentration monitoring in hemodialysis patients with end stage kidney disease: A retrospective cohort study5
5
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward4
4
Issue Information4
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained‐release formulations4
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds4
Prediction of basic drug exposure in milk using a lactation model algorithm integrated within a physiologically based pharmacokinetic model4
Intestinal absorption pathways of lisinopril: Mechanistic investigations4
Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l‐lactate transport in the hepatocellular carcinoma cell line4
Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2‐MATE1)4
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery3
3
3
Issue Information3
Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells3
3
Icaritin exhibits potential drug–drug interactions through the inhibition of human UDP‐glucuronosyltransferase in vitro3
Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice3
Characterization of AST‐001 non‐clinical pharmacokinetics: A novel selective AKR1C3‐activated prodrug in mice, rats, and cynomolgus monkeys3
Profiling pharmacokinetics of double‐negative T cells and cytokines via a single intravenous administration in NSG mice3
Issue Information3
3
Metabolism of testosterone and progesterone by cytochrome P450 2C19 allelic variants3
Issue Information3
In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies3
Transition of average drug‐to‐antibody ratio of trastuzumab deruxtecan in systemic circulation in monkeys using a hybrid affinity capture liquid chromatography‐tandem mass spectrometry2
Drug‐drug interaction between diclofenac and gamma‐hydroxybutyric acid2
2
Gender difference in the pharmacokinetics and metabolism of VX‐548 in rats2
In vitro and in silico interactions of antiulcer, glucocorticoids and urological drugs on human carbonic anhydrase I and II isozymes2
Influence of piperine and omeprazole on the regional absorption of Daclatasvir from rabbit intestine1
In vivo monitoring of brain pharmacokinetics and pharmacodynamics with cerebral open flow microperfusion1
Pharmacokinetic–pharmacodynamic modeling of the active components of Shenkang injection in rats with chronic renal failure and its protective effect on damaged renal cells1
Pregnenolone Sulfate Permeation at the Blood–Brain Barrier is Independent of OATP2B1—In Vivo and In Vitro Insights1
An Optimised Mobilenet V2 Attention Parallel Network for Predicting Drug–Drug Interactions Through Combining Local and Global Features1
Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk1
Evaluation of bleeding and anticoagulation markers by edoxaban and low‐dose cyclosporine: A case series study1
Optimizing transcardial perfusion of small molecules and biologics for brain penetration and biodistribution studies in rodents1
Issue Information1
0
Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers0
Influences of Magnesium Isoglycyrrhizinate on the Pharmacokinetics of Almonertinib in Rats and Its Potential Mechanisms0
Regional distributions of curcumin and tetrahydrocurcumin in the liver and small intestine of rats when orally co‐administered with quercetin and paeoniflorin0
0
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator0
Evaluation on absorption risks of amentoflavone after oral administration in rats0
Investigating CNS distribution of PF‐05212377, a P‐glycoprotein substrate, by translation of 5‐HT6 receptor occupancy from non‐human primates to humans0
Linking in vitro–in vivo extrapolations with physiologically based modeling to inform drug and formulation development0
Population pharmacokinetics of oral levofloxacin in healthy volunteers and dosing optimization for multidrug‐resistant tuberculosis therapy0
Enhanced oral bioavailability of capsaicin‐loaded microencapsulation complex via electrospray technology: Preparation, in vitro and in vivo evaluation0
0
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling0
Special issue on applications of in vitro, in vivo, and modeling and simulation tools for central nervous system drug disposition0
0
0
Physiologically‐based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans0
Decreased plasma exposure of clopidogrel active metabolite in rats after long‐term treatment with clopidogrel0
Clinical application of vancomycin population pharmacokinetics model in patients with hematological diseases and neutropenia0
A limited sampling model to estimate the area under the curve of mycophenolic acid in hematopoietic stem cell transplantation recipients0
0
Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients0
Model‐informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations0
Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats0
Issue Information0
Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives0
Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure0
Comparative in silico prediction of P‐glycoprotein‐mediated transport for 2010–2020 US FDA‐approved drugs using six Web‐tools0
Issue Information0
Computational exploration of microsomal cytochrome P450 3A1 enzyme modulation by phytochemicals ofCichorium intybusL.: Insights into drug metabolism0
Nanostructured Lipid Carriers‐Based Topical Gel of Betulinic Acid: In Vitro, In Vivo Evaluation and Dermatokinetic Analysis0
Influence of Gegenqinlian decoction on pharmacokinetics and pharmacodynamics of saxagliptin in type 2 diabetes mellitus rats0
Effects of aged garlic and ginkgo biloba extracts on the pharmacokinetics of sofosbuvir in rats0
Exploring the Potential of Nasal Drug Delivery for Brain Targeted Therapy: A Detailed Analysis0
In vitro–in vivo extrapolation of bexarotene metabolism in the presence of chronic kidney disease and acute kidney injury in rat using physiologically based pharmacokinetic modeling and extrapo0
Exploring in vitro solubility of lamotrigine in physiologically mimetic conditions to prospect the in vivo dissolution in pediatric population0
Effect of ABCB1 gene variants on rivaroxaban pharmacokinetic and hemorrhage events occurring in patients with non‐valvular atrial fibrillation0
Heterogeneous brain distribution of bumetanide following systemic administration in rats0
Issue Information0
0
Application of Physiologically Based Pharmacokinetic Model to Compare the Biodistribution of Liposomal Amphotericin B With Conventional Amphotericin B Deoxycholate in Humans0
0
Comparison of biomarker and chromatographic analytical approaches to pharmacokinetic study of sitagliptin0
Metabolic interaction between biflavonoids in Ginkgo biloba leaves and tacrolimus0
Changes in uridine 5′‐diphospho‐glucuronosyltransferase 1A6 expression by histone deacetylase inhibitor valproic acid0
Issue Information0
0
Renal Interstitial Distribution of Full‐Length IgG and Fab Fragments in Unilateral Ureteral Obstruction‐Induced Fibrotic Kidneys0
Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model0
The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery0
Vicagrel is hydrolyzed by Raf kinase inhibitor protein in human intestine0
Issue Information0
Enalapril increases the urinary excretion of metformin in rats by inducing multidrug and toxin excretion protein 1 in the kidney0
In‐depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: Part I – Applications and rationale behind the use of open source‐code software0
The Influence of a Rat Model of Depression and Gastric Ulcer on the Pharmacokinetics of Encorafenib0
In Vivo Animal Spices and Experimental Technique to Evaluate Sustained Release Granules0
Inhibition Mechanism of Ketamine‐Apatinib by CYP2C9 and 3A4: A Prediction of Possible Drug‐Drug Interaction0
Issue Information0
0
Nanocrystal solid dispersion of fuzapladib free acid with improved oral bioavailability0
In‐depth analysis of patterns in selection of different physiologically‐based pharmacokinetic modeling tools: Part II — Assessment of model reusability and comparison between open and non‐open source‐0
Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial0
Association between α‐defensin 5 and the expression and function of P‐glycoprotein in differentiated intestinal Caco‐2 cells0
Issue Information0
Develop adult extrapolation to pediatrics and pediatric dose optimization based on the physiological pharmacokinetic model of azithromycin0
Selective inhibitory effects of suberosin on CYP1A2 in human liver microsomes0
Issue Information0
0
Issue Information0
0
Recent advances in the in vitro and in vivo methods to assess impact of P‐glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition0
Febuxostat and its major acyl glucuronide metabolite are potent inhibitors of organic anion transporter 3: Implications for drug‐drug interactions with rivaroxaban0
Model‐based interspecies interpretation of botulinum neurotoxin type A on muscle‐contraction inhibition0
Quantitative analysis of the impact of membrane permeability on intestinal first‐pass metabolism of CYP3A substrates0
Issue Information0
Issue Information0
Issue Information0
Mouse Cyp2c expression and zonation structure in the liver begins in the early neonatal stage0
0.31781387329102